

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**CLAIMS**

**Please CANCEL claims 1 to 40.**

41. (New) A composition for the delivery of gaseous nitric oxide (NO), comprising a compound capable of forming a reversible bond or association with NO, wherein said compound is a water miscible organic compound, comprising at least one hydroxyl group.

42. (New) A composition for the delivery of gaseous nitric oxide (NO), comprising a compound capable of forming a reversible bond or association with NO, wherein said compound is a water miscible organic compound, comprising at least one hydroxyl group, wherein said compound is a carbohydrate compound.

43. (New) The composition according to claim 42, wherein said compound is a monosaccharide or a derivative thereof.

44. (New) The composition according to claim 42, wherein said compound is selected from the group consisting of glucose, fructose, galactose and ribose.

45. (New) The composition according to claim 42, wherein said compound is a monosaccharide alcohol.

46. (New) The composition according to claim 42, wherein said compound is chosen sorbitol or mannitol.

47. (New) The composition according to claim 42, wherein said compound is a modified monosaccharide.

48. (New) The composition according to claim 42, wherein said compound is fucose, 2-deoxy-ribose, or 1-O-methyl-ribose.

49. (New) The composition according to claim 42, wherein said compound is a disaccharide or a higher carbohydrate polymer of a monosaccharide or derivative thereof.

50. (New) The composition according to claim 42, wherein said compound is a disaccharide or higher polysaccharide of glucose, fructose, galactose, ribose, sorbitol, mannitol, fucose, 2-deoxy-ribose, or 1-O-methyl-ribose.

51. (New) The composition according to claim 42, wherein said compound is selected from the group consisting of sucrose, lactobionic acid, inulin, dextran, and fucoidan.

52. (New) A composition for the delivery of gaseous nitric oxide (NO), comprising a compound capable of forming a reversible bond or association with NO, wherein said compound is a water miscible organic compound comprising at least one hydroxyl group, wherein said compound is an alcohol or a derivative thereof.

53. (New) The composition according to claim 52, wherein said compound is a monohydric alcohol or a derivative thereof.

54. (New) The composition according to claim 52, wherein said compound is selected from the group consisting of 1-propanol, 2-propanol, sorbitol, and mannitol.

55. (New) The composition according to claim 52, wherein said compound is a dihydric alcohol.
56. (New) The composition according to claim 52, wherein said compound is 1, 2-propanediol or 1,3-propanediol.
57. (New) The composition according to claim 52, wherein said compound is a trihydric alcohol.
58. (New) The composition according to claim 52, wherein said compound is glycerol.
59. (New) The composition according to claim 52, wherein said compound is a polymer of alcohol molecules or derivatives thereof.
60. (New) The composition according to claim 52, wherein said compound is a polyethylene glycol.
61. (New) A composition for the delivery of gaseous nitric oxide (NO), comprising a compound capable of forming a reversible bond or association with NO, wherein said compound is a water miscible organic compound, comprising at least one hydroxyl group, wherein said compound is a modified amino acid, peptide, polypeptide or protein.
62. (New) The composition according to claim 61, wherein said compound is a modified amino acid where the primary amino group has been substituted to a secondary amino group.
63. (New) The composition according to claim 61, wherein said compound is N-acetyl-cysteine.
64. (New) The composition according to claim 61, wherein said compound is albumin.

65. (New) The composition according to claim 41, wherein said composition is formulated as a lipid emulsion.

66. (New) The composition according to claim 41, formulated for topical, rectal, vaginal, urethral, intravesical, nasal, ocular, sublingual, buccal, oral, enteral, intravenous, intraarterial, intratracheal, intramuscular or subcutaneous administration.

67. (New) The composition according to claim 42, formulated for topical, rectal, vaginal, urethral, intravesical, nasal, ocular, sublingual, buccal, oral, enteral, intravenous, intraarterial, intratracheal, intramuscular or subcutaneous administration.

68. (New) The composition according to claim 52, formulated for topical, rectal, vaginal, urethral, intravesical, nasal, ocular, sublingual, buccal, oral, enteral, intravenous, intraarterial, intratracheal, intramuscular or subcutaneous administration.

69. (New) The composition according to claim 61, formulated for topical, rectal, vaginal, urethral, intravesical, nasal, ocular, sublingual, buccal, oral, enteral, intravenous, intraarterial, intratracheal, intramuscular or subcutaneous administration.

70. (New) The composition according to claim 66, wherein the composition contains substantially no oxygen.

71. (New) The composition according to claim 67, wherein the composition contains substantially no oxygen.

72. (New) The composition according to claim 68, wherein the composition contains substantially no oxygen.

73. (New) The composition according to claim 69, wherein the composition contains substantially no oxygen.

74. (New) The composition according to claim 70, wherein the composition contains substantially no oxygen.

75. (New) A method for the treatment, alleviation or prevention of a condition chosen among acute pulmonary vasoconstriction of different genesis, pulmonary embolism, pulmonary hypertension of different genesis, including primary hypertension and secondary hypertension, systemic hypertension of different genesis, portal hypertension of different genesis, acute heart failure, acidosis, inflammation of the lung, adult respiratory distress syndrome, acute pulmonary edema, acute mountain sickness, asthma, hypoxia of different genesis, inflammation of different genesis; wound healing, and conditions where smooth muscle relaxation is needed, wherein a compound, capable of delivering NO is given to said patient.